Control of adaptive immunity by vitamin D receptor agonists

Vitamin D

Volumn , Issue , 2011, Pages 1789-1809

  Adorini, Luciano ^a  

^a INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884738510     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10092-7     Document Type: Chapter

References (223)

1. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
2. Kumar H., Kawai T., Akira S. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 2009, 388:621-625.
3. Brodsky I.E., Medzhitov R. Targeting of immune signalling networks by bacterial pathogens. Nature Cell Biol. 2009, 11:521-526.
4. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 2010, 28:445-489.
5. Zhou L., Chong M.M., Littman D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30:646-655.
6. O'Shea J.J., Paul W.E. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010, 327:1098-1102.
7. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J. 2001, 15:2579-2585.
8. Mathieu C., Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med. 2002, 8:174-179.
9. Griffin M.D., Xing N., Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu. Rev. Nutr. 2003, 23:117-145.
10. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 2008, 4:404-412.
11. Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 2010, 10:482-496.
12. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 1998, 13:325-349.
13. Carlberg C., Seuter S. The vitamin D receptor. Dermatol. Clin. 2007, 25:515-523. viii.
14. Provvedini D.M., Tsoukas C.D., Deftos L.J., Manolagas S.C. 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 1983, 221:1181-1183.
15. Brennan A., Katz D., Nunn J., Barker S., Hewison M., Fraher L., et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology 1987, 61:457-461.
16. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374:334-338.
17. 3 inhibits antigen-induced T cell activation. J. Immunol. 1984, 133:1748-1754.
18. van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 2005, 97:93-101.
19. Cantorna M.T. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog. Biophys. Mol. Biol. 2006, 92:60-64.
20. Arnson Y., Amital H., Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann. Rheum. Dis. 2007, 66:1137-1142.
21. Adorini L., Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Human Immunol. 2009, 70:345-352.
22. Overbergh L., Decallonne B., Valckx D., Verstuyf A., Depovere J., Laureys J., et al. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin. Exp. Immunol. 2000, 120:139-146.
23. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
24. Hewison M., Freeman L., Hughes S.V., Evans K.N., Bland R., Eliopoulos A.G., et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 2003, 170:5382-5390.
25. Sigmundsdottir H., Pan J., Debes G.F., Alt C., Habtezion A., Soler D., et al. DCs metabolize sunlight-induced vitamin D3 to "program" T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 2007, 8:285-293.
26. Cadranel J., Garabedian M., Milleron B., Guillozo H., Akoun G., Hance A.J. 1,25(OH)2D3 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J. Clin. Invest. 1990, 85:1588-1593.
27. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
28. Griffin M.D., Lutz W., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 22:22.
29. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
30. Steinman R.M., Idoyaga J. Features of the dendritic cell lineage. Immunol. Rev. 2010, 234:5-17.
31. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nature Rev. Immunol. 2002, 2:151-161.
32. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
33. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23:275-306.
34. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
35. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
36. Josefowicz S.Z., Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009, 30:616-625.
37. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 2010, 11:7-13.
38. Allan S.E., Broady R., Gregori S., Himmel M.E., Locke N., Roncarolo M.G., et al. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol. Rev. 2008, 223:391-421.
39. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 2003, 198:235-247.
40. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 2002, 23:445-449.
41. Adler H.S., Steinbrink K. Tolerogenic dendritic cells in health and disease: friend and foe!. Eur. J. Dermatol. 2007, 17:476-491.
42. Belkaid Y., Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 2008, 29:362-371.
43. Puccetti P., Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat. Rev. Immunol. 2007, 7:817-823.
44. Colonna M., Nakajima H., Cella M. A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin. Immunol. 2000, 12:121-127.
45. Delgado M., Gonzalez-Rey E., Ganea D. Vasoactive intestinal peptide: the dendritic cell → regulatory T cell axis. Ann. NY. Acad. Sci. 2006, 1070:233-238.
46. Rutella S., Bonanno G., Procoli A., Mariotti A., de Ritis D.G., Curti A., et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006, 108:218-227.
47. Wakkach A., Fournier N., Brun V., Breittmayer J.P., Cottrez F., Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003, 18:605-617.
48. Watanabe N., Wang Y.H., Lee H.K., Ito T., Wang Y.H., Cao W., et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005, 436:1181-1185.
49. Mahnke K., Johnson T.S., Ring S., Enk A.H. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J. Dermatol. Sci. 2007, 46:159-167.
50. Houot R., Perrot I., Garcia E., Durand I., Lebecque S. Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J. Immunol. 2006, 176:5293-5298.
51. Veldhoen M., Moncrieffe H., Hocking R.J., Atkins C.J., Stockinger B. Modulation of dendritic cell function by naive and regulatory CD4+ T cells. J. Immunol. 2006, 176:6202-6210.
52. Rutella S., De Cristofaro R., Ferraccioli G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Human Immunol. 2009, 70:360-373.
53. Allison A.C. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000, 47:63-83.
54. Lagaraine C., Lebranchu Y. Effects of immunosuppressive drugs on dendritic cells and tolerance induction. Transplantation 2003, 75:37S-42S.
55. Woltman A.M., van Kooten C. Functional modulation of dendritic cells to suppress adaptive immune responses. J. Leukoc. Biol. 2003, 73:428-441.
56. Hackstein H., Thomson A.W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 2004, 4:24-34.
57. Adorini L., Giarratana N., Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin. Immunol. 2004, 16:127-134.
58. Thomson A.W., Turnquist H.R., Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 2009, 9:324-337.
59. Woltman A.M., de Fijter J.W., Kamerling S.W., Paul L.C., Daha M.R., van Kooten C. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur. J. Immunol. 2000, 30:1807-1812.
60. Colic M., Stojic-Vukanic Z., Pavlovic B., Jandric D., Stefanoska I. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin. Exp. Immunol. 2003, 134:63-69.
61. Szabo G., Gavala C., Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J. Investig. Med. 2001, 49:442-449.
62. Thomas J.M., Hubbard W.J., Sooudi S.K., Thomas F.T. STEALTH matters: a novel paradigm of durable primate allograft tolerance. Immunol. Rev. 2001, 183:223-233.
63. Buckland M., Lombardi G. Aspirin and the induction of tolerance by dendritic cells. Handb. Exp. Pharmacol. 2009, 197-213.
64. Millard A.L., Mertes P.M., Ittelet D., Villard F., Jeannesson P., Bernard J. Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages. Clin. Exp. Immunol. 2002, 130:245-255.
65. Svajger U., Vidmar A., Jeras M. Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ILT3 and ILT4. Int. Immunopharmacol. 2008, 8:997-1005.
66. Verhasselt V., Vanden Berghe W., Vanderheyde N., Willems F., Haegeman G., Goldman M. N-acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level: association with NF-kappaB inhibition. J. Immunol. 1999, 162:2569-2574.
67. 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 2001, 167:1945-1953.
68. Izawa A., Sayegh M.H., Chandraker A. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction?. Transplant. Proc. 2004, 36:570S-573S.
69. Saemann M.D., Kelemen P., Bohmig G.A., Horl W.H., Zlabinger G.J. Hyporesponsiveness in alloreactive T-cells by NF-kappaB inhibitor-treated dendritic cells: resistance to calcineurin inhibition. Am. J. Transplant. 2004, 4:1448-1458.
70. Game D.S., Hernandez-Fuentes M.P., Lechler R.I. Everolimus and Basiliximab permit suppression by human CD4CD25 cells in vitro. Am. J. Transplant. 2005, 5:454-464.
71. Trembleau S., Germann T., Gately M.K., Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today 1995, 16:383-386.
72. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25:280-288.
73. Martin E., O'Sullivan B., Low P., Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003, 18:155-167.
74. Auphan N., Di Donato J., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kB activity through induction of IkB synthesis. Science 1995, 270:286-290.
75. Giarratana N., Penna G., Amuchastegui S., Mariani R., Daniel K.C., Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J. Immunol. 2004, 173:2280-2287.
76. Dong X., Craig T., Xing N., Bachman L.A., Paya C.V., Weih F., et al. Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J. Biol. Chem. 2003, 278:49378-49385.
77. Penna G., Amuchastegui S., Giarratana N., Daniel K.C., Vulcano M., Sozzani S., et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol. 2007, 178:145-153.
78. Széles L., Keresztes G., Töröcsik D., Balajthy Z., Krenács L., Póliska S., et al. 1,25-Dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J. Immunol. 2009, 182:2074-2083.
79. Chen X., Jensen P.E. Cutting edge: primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J. Immunol. 2007, 179:2046-2050.
80. Thomson A.W. Tolerogenic dendritic cells: all present and correct?. Am. J. Transplant. 2010, 10:214-219.
81. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 2001, 193:233-238.
82. 3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51:1367-1374.
83. Gorman S., Kuritzky L.A., Judge M.A., Dixon K.M., McGlade J.P., Mason R.S., et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J. Immunol. 2007, 179:6273-6283.
84. Daniel C., Sartory N.A., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 2008, 324:23-33.
85. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 2002, 195:603-616.
86. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
87. Klotz L., Dani I., Edenhofer F., Nolden L., Evert B., Paul B., et al. Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy. J. Immunol. 2007, 178:2122-2131.
88. Wohlfert E.A., Nichols F.C., Nevius E., Clark R.B. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J. Immunol. 2007, 178:4129-4135.
89. Hontecillas R., Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J. Immunol. 2007, 178:2940-2949.
90. Yokoyama W.M. What goes up must come down: the emerging spectrum of inhibitory receptors. J. Exp. Med. 1997, 186:1803-1808.
91. Colonna M., Nakajima H., Navarro F., Lopez-Botet M. A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J. Leukoc. Biol. 1999, 66:375-381.
92. Cella M., Dohring C., Samaridis J., Dessing M., Brockhaus M., Lanzavecchia A., et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J. Exp. Med. 1997, 185:1743-1751.
93. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. 2002, 3:237-243.
94. Vlad G., Suciu-Foca N. Resurgence or emergence of CD8+ Ts. Human Immunol. 2008, 69:679-680.
95. Manavalan J.S., Kim-Schulze S., Scotto L., Naiyer A.J., Vlad G., Colombo P.C., et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int. Immunol. 2004, 16:1055-1068.
96. Takai T., Ono M. Activating and inhibitory nature of the murine paired immunoglobulin-like receptor family. Immunol. Rev. 2001, 181:215-222.
97. Liu J., Liu Z., Witkowski P., Vlad G., Manavalan J.S., Scotto L., et al. Rat CD8+ FoxP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl. Immunol. 2004, 13:239-247.
98. Cortesini R. Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3). Jop. 2007, 8:697-703.
99. Vlad G., Chang C.C., Colovai A.I., Vasilescu E.R., Cortesini R., Suciu-Foca N. Membrane and soluble ILT3 are critical to the generation of T suppressor cells and induction of immunological tolerance. Int. Rev. Immunol. 2010, 29:119-132.
100. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 1999, 5:919-923.
101. Penna G., Sozzani S., Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J. Immunol. 2001, 167:1862-1866.
102. Penna G., Roncari A., Amuchastegui S., Daniel K.C., Berti E., Colonna M., et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005, 106:3490-3497.
103. Gilliet M., Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 2002, 195:695-704.
104. Xing N., Maldonado L.M., Bachman L.A., McKean D.J., Kumar R., Griffin M.D. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem. Biophys. Res. Commun. 2002, 297:645-652.
105. Fedoric B., Krishnan R. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunol. Lett. 2008, 120:49-56.
106. Turnquist H.R., Raimondi G., Zahorchak A.F., Fischer R.T., Wang Z., Thomson A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 2007, 178:7018-7031.
107. Xie J.H., Nomura N., Lu M., Chen S.L., Koch G.E., Weng Y., et al. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J. Leukoc. Biol. 2003, 73:771-780.
108. Frigerio S., Junt T., Lu B., Gerard C., Zumsteg U., Hollander G.A., et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat. Med. 2002, 8:1414-1420.
109. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 2001, 194:847-853.
110. Giarratana N., Penna G., Adorini L. Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Methods Mol. Biol. 2007, 380:285-311.
111. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
112. Penna G., Vulcano M., Roncari A., Facchetti F., Sozzani S., Adorini L. Differential chemokine production by myeloid and plasmacytoid dendritic cells. J. Immunol. 2002, 169:6673-6676.
113. Swiecki M., Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 2010, 234:142-162.
114. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 2009, 27:693-733.
115. Fallarino F., Gizzi S., Mosci P., Grohmann U., Puccetti P. Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. Curr. Drug. Metab. 2007, 8:209-216.
116. Baeke F., Korf H., Overbergh L., van Etten E., Verstuyf A., Gysemans C., et al. Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D(3) in the immune system. J. Steroid Biochem. Mol. Biol. 2010, 121:221-227.
117. von Essen M.R., Kongsbak M., Schjerling P., Olgaard K., Odum N., Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat. Immunol. 2010, 11:344-349.
118. 3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 1983, 57:1308-1310.
119. 3. J. Clin. Invest. 1987, 79:1659-1664.
120. Lemire J.M., Archer D.C., Beck L., Spiegelberg H.L. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J. Nutrition 1995, 125:1704S-1708S.
121. Mattner F., Smiroldo S., Galbiati F., Muller M., Di Lucia P., Poliani P.L., et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur. J. Immunol. 2000, 30:498-508.
122. Jeffery L.E., Burke F., Mura M., Zheng Y., Qureshi O.S., Hewison M., et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 2009, 183:5458-5467.
123. 3: direct inhibition NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol. Cell Biol. 1995, 15:5789-5799.
124. 3-mediated effects. J. Immunol. 1998, 160:209-218.
125. 3: a transcriptional modulator of the IFN-γ gene. Eur. J. Immunol. 1998, 28:3017-3030.
126. 3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β1 and IL-4. J. Immunol. 1998, 160:5314-5319.
127. Cippitelli M., Fionda C., Di Bona D., Di Rosa F., Lupo A., Piccoli M., et al. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J. Immunol. 2002, 168:1154-1166.
128. Suzuki I., Martin S., Boursalian T.E., Beers C., Fink P.J. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. J. Immunol. 2000, 165:5537-5543.
129. Rescigno M., Piguet V., Valzasina B., Lens S., Zubler R., French L., et al. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J. Exp. Med. 2000, 192:1661-1668.
130. Penna G., Adorini L. 1Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000, 164:2405-2411.
131. Boonstra A., Barrat F.J., Crain C., Heath V.L., Savelkoul H.F., O'Garra A. 1Alpha,25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T Cells to enhance the development of Th2 cells. J. Immunol. 2001, 167:4974-4980.
132. Overbergh L., Decallonne B., Waer M., Rutgeerts O., Valckx D., Casteels K.M., et al. 1Alpha,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes 2000, 49:1301-1307.
133. Nashold F.E., Hoag K.A., Goverman J., Hayes C.E. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2001, 119:16-29.
134. Staeva-Vieira T.P., Freedman L.P. 1,25-Dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J. Immunol. 2002, 168:1181-1189.
135. Penna G., Amuchastegui S., Cossetti C., Aquilano F., Mariani R., Sanvito F., et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J. Immunol. 2006, 177:8504-8511.
136. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13:139-145.
137. Pedersen A.W., Holmstrom K., Jensen S.S., Fuchs D., Rasmussen S., Kvistborg P., et al. Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin. Exp. Immunol. 2009, 157:48-59.
138. Tang J., Zhou R., Luger D., Zhu W., Silver P.B., Grajewski R.S., et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J. Immunol. 2009, 182:4624-4632.
139. Brustle A., Heink S., Huber M., Rosenplanter C., Stadelmann C., Yu P., et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat. Immunol. 2007, 8:958-966.
140. Gauzzi M.C., Purificato C., Conti L., Adorini L., Belardelli F., Gessani S. IRF-4 expression in the human myeloid lineage: up-regulation during dendritic cell differentiation and inhibition by 1{alpha},25-dihydroxyvitamin D3. J. Leukoc. Biol. 2005, 77:944-947.
141. Morgan J.W., Morgan D.M., Lasky S.R., Ford D., Kouttab N., Maizel A.L. Requirements for induction of vitamin D-mediated gene regulation in normal human B lymphocytes. J. Immunol. 1996, 157:2900-2908.
142. Heine G., Anton K., Henz B.M., Worm M. 1Alpha,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. Eur. J. Immunol. 2002, 32:3395-3404.
143. Heine G., Niesner U., Chang H.D., Steinmeyer A., Zugel U., Zuberbier T., et al. 1,25-Dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur. J. Immunol. 2008, 38:2210-2218.
144. Kunkel E.J., Butcher E.C. Plasma-cell homing. Nat. Rev. Immunol. 2003, 3:822-829.
145. Shirakawa A.K., Nagakubo D., Hieshima K., Nakayama T., Jin Z., Yoshie O. 1,25-Dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B cells. J. Immunol. 2008, 180:2786-2795.
146. Millen A.E., Bodnar L.M. Vitamin D assessment in population-based studies: a review of the issues. Am. J. Clin. Nutr. 2008, 87:S1102-S1105.
147. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006, 84:18-28.
148. Holick M.F. Vitamin D status: measurement, interpretation, and clinical application. Ann. Epidemiol. 2009, 19:73-78.
149. Cantorna M.T., Mahon B.D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp. Biol. Med. 2004, 229:1136-1142.
150. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
151. Grant W.B. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog. Biophys. Mol. Biol. 2006, 92:65-79.
152. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
153. Brown S.J. The role of vitamin D in multiple sclerosis. Ann. Pharmacother. 2006, 40:1158-1161.
154. Niino M., Fukazawa T., Kikuchi S., Sasaki H. Therapeutic potential of vitamin D for multiple sclerosis. Curr. Med. Chem. 2008, 15:499-505.
155. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
156. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch. Dis. Child. 2008, 93:512-517.
157. Merlino L.A., Curtis J., Mikuls T.R., Cerhan J.R., Criswell L.A., Saag K.G. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arth. Rheum. 2004, 50:72-77.
158. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 2006, 5:114-117.
159. Costenbader K.H., Feskanich D., Holmes M., Karlson E.W., Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 2008, 67:530-535.
160. Pappa H.M., Grand R.J., Gordon C.M. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm. Bowel Dis. 2006, 12:1162-1174.
161. Valdivielso J.M., Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta. Int. J. Clin. Chem. 2006, 371:1-12.
162. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 2005, 26:662-687.
163. Cantorna M.T., Hayes C.E., DeLuca H.F. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J. Nutr. 1998, 128:68-72.
164. Larsson P., Mattsson L., Klareskog L., Johnsson C. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin. Exp. Immunol. 1998, 114:277-283.
165. Tetlow L.C., Woolley D.E. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res. 1999, 1:63-70.
166. Colin E.M., Asmawidjaja P.S., van Hamburg J.P., Mus A.M., van Driel M., Hazes J.M., et al. 1,25-Dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arth. Rheum. 2010, 62:132-142.
167. Cutolo M., Otsa K., Uprus M., Paolino S., Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun. Rev. 2007, 7:59-64.
168. Pelajo C.F., Lopez-Benitez J.M., Miller L.C. Vitamin D and autoimmune rheumatologic disorders. Autoimmun. Rev. 2010, 9:507-510.
169. Andjelkovic Z., Vojinovic J., Pejnovic N., Popovic M., Dujic A., Mitrovic D., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 1999, 17:453-456.
170. Santiago-Raber M.L., Laporte C., Reininger L., Izui S. Genetic basis of murine lupus. Autoimmun. Rev. 2004, 3:33-39.
171. Abe J., Nakamura K., Takita Y., Nakano T., Irie H., Nishii Y. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3. J. Nutr. Sci. Vitaminol. (Tokyo) 1990, 36:21-31.
172. Lemire J.M., Ince A., Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992, 12:143-148.
173. Cutolo M., Otsa K. Review: vitamin D, immunity and lupus. Lupus 2008, 17:6-10.
174. Linker-Israeli M., Elstner E., Klinenberg J.R., Wallace D.J., Koeffler H.P. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin. Immunol. 2001, 99:82-93.
175. Ruiz-Irastorza G., Egurbide M.V., Olivares N., Martinez-Berriotxoa A., Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008, 47:920-923.
176. Uskokovic M.R., Norman A.W., Manchand P.S., Studzinski G.P., Campbell M.J., Koeffler H.P., et al. Highly active analogs of 1alpha,25-dihydroxyvitamin D(3) that resist metabolism through C-24
177. Adorini L., Penna G., Giarratana N., Mariani R., Uskokovic M. Inhibition of type 1 diabetes development by vitamin D receptor agonists. Curr. Med. Chem. 2005, 4:645-651.
178. Gysemans C., van Etten E., Overbergh L., Giulietti A., Eelen G., Waer M., et al. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes 2008, 57:269-275.
179. Kahles H., Morahan G., Todd J.A., Badenhoop K. Association analyses of the vitamin D receptor gene in 1654 families with type I diabetes. Genes Immun. 2009, 10(Suppl. 1):S60-63.
180. Bailey R., Cooper J.D., Zeitels L., Smyth D.J., Yang J.H., Walker N.M., et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 2007, 56:2616-2621.
181. Mohr S.B., Garland C.F., Gorham E.D., Garland F.C. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 2008, 51:1391-1398.
182. The EURODIAB Substudy 2 Study Group Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. Diabetologia 1999, 42:51-54.
183. Smolders J., Damoiseaux J., Menheere P., Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 2008, 194:7-17.
184. Muthian G., Raikwar H.P., Rajasingh J., Bright J.J. 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J. Neurosci. Res. 2006, 83:1299-1309.
185. Spach K.M., Nashold F.E., Dittel B.N., Hayes C.E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:6030-6037.
186. Pedersen L.B., Nashold F.E., Spach K.M., Hayes C.E. 1,25-Dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J. Neurosci. Res. 2007, 85:2480-2490.
187. Correale J., Ysrraelit M.C., Gaitan M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132:1146-1160.
188. Myhr K.M. Vitamin D treatment in multiple sclerosis. J. Neural. Sci. 2009, 286:104-108.
189. Shih D.Q., Targan S.R. Insights into IBD pathogenesis. Curr. Gastroenterol. Rep. 2009, 11:473-480.
190. Froicu M., Cantorna M.T. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007, 8:5.
191. Kong J., Zhang Z., Musch M.W., Ning G., Sun J., Hart J., et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G208-216.
192. Mayer L. Evolving paradigms in the pathogenesis of IBD. J. Gastroenterol. 2010, 45:9-16.
193. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
194. Zhu Y., Mahon B.D., Froicu M., Cantorna M.T. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol. 2005, 35:217-224.
195. Laverny G., Penna G., Vetrano S., Correale C., Nebuloni M., Danese S., et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol. Lett. 2010, 131:49-58.
196. Stio M., Martinesi M., Bruni S., Treves C., Mathieu C., Verstuyf A., et al. The vitamin D analogue TX 527 blocks NF-kappaB activation in peripheral blood mononuclear cells of patients with Crohn's disease. J. Steroid Biochem. Mol. Biol. 2007, 103:51-60.
197. Daniel C., Radeke H.H., Sartory N.A., Zahn N., Zuegel U., Steinmeyer A., et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J. Pharmacol. Exp. Ther. 2006, 319:622-631.
198. Flanagan J.N., Young M.V., Persons K.S., Wang L., Mathieu J.S., Whitlatch L.W., et al. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006, 26:2567-2572.
199. Motrich R.D., Maccioni M., Riera C.M., Rivero V.E. Autoimmune prostatitis: state of the art. Scand. J. Immunol. 2007, 66:217-227.
200. Crescioli C., Ferruzzi P., Caporali A., Scaltriti M., Bettuzzi S., Mancina R., et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. 2004, 150:591-603.
201. Steiner G.E., Djavan B., Kramer G., Handisurya A., Newman M., Lee C., et al. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev. Urol. 2002, 4:171-177.
202. Adorini L., Penna G., Amuchastegui S., Cossetti C., Aquilano F., Mariani R., et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J. Steroid Biochem. Mol. Biol. 2007, 103:689-693.
203. Motrich R.D., van Etten E., Depovere J., Riera C.M., Rivero V.E., Mathieu C. Impact of vitamin D receptor activity on experimental autoimmune prostatitis. J. Autoimmun. 2009, 32:140-148.
204. Adorini L., Penna G., Fibbi B., Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann. NY Acad. Sci. 2010, 1193:146-152.
205. Crescioli C., Morelli A., Adorini L., Ferruzzi P., Luconi M., Vannelli G.B., et al. Human bladder as a novel target for vitamin D receptor ligands. J. Clin. Endocrinol. Metab. 2005, 90:962-972.
206. Taniguchi K., Katagiri K., Kashiwagi H., Harada S., Sugimoto Y., Shimizu Y., et al. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model. J. Steroid Biochem. Mol. Biol. 2010, 121:204-207.
207. Penna G., Fibbi B., Amuchastegui S., Corsiero E., Laverny G., Silvestrini E., et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009, 69:480-493.
208. Comeglio P., Chavalmane A.K., Fibbi B., Filippi S., Marchetta M., Marini M., et al. Human prostatic urethra expresses Vitamin D receptor and responds to Vitamin D receptor ligation. J. Endocrinol. Invest. 2010, 33:730-738.
209. Colli E., Rigatti P., Montorsi F., Artibani W., Petta S., Mondaini N., et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol. 2006, 49:82-86.
210. Vulcano M., Struyf S., Scapini P., Cassatella M., Bernasconi S., Bonecchi R., et al. Unique regulation of CCL18 production by maturing dendritic cells. J. Immunol. 2003, 170:3843-3849.
211. Piemonti L., Monti P., Sironi M., Fraticelli P., Leone B.E., Dal Cin E., et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 2000, 164:4443-4451.
212. Griffin M.D., Lutz W.H., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem. Biophys. Res. Commun. 2000, 270:701-708.
213. Berer A., Stockl J., Majdic O., Wagner T., Kollars M., Lechner K., et al. 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp. Hematol. 2000, 28:575-583.
214. Canning M.O., Grotenhuis K., de Wit H., Ruwhof C., Drexhage H.A. 1-Alpha,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur. J. Endocrinol. 2001, 145:351-357.
215. Inaba M., Nishizawa Y., Song K., Tanishita H., Okuno S., Miki T., et al. Partial protection of 1 alpha-hydroxyvitamin D3 against the development of diabetes induced by multiple low-dose streptozotocin injection in CD-1 mice. Metabolism 1992, 41:631-635.
216. Mathieu C., Waer M., Laureys J., Rutgeerts O., Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994, 37:552-558.
217. Mathieu C., Waer M., Casteels K., Laureys J., Bouillon R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 1995, 136:866-872.
218. Casteels K.M., Mathieu C., Waer M., Valckx D., Overbergh L., Laureys J.M., et al. Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. Endocrinology 1998, 139:95-102.
219. Lemire J.M., Archer D.C. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 1991, 87:1103-1107.
220. 3. J. Neuroimmunol. 1995, 61:151-160.
221. Cantorna M.T., Munsick C., Bemiss C., Mahon B.D. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 2000, 130:2648-2652.
222. Koizumi T., Nakao Y., Matsui T., Nakagawa T., Matsuda S., Komoriya K., et al. Effects of corticosteroid and 1,24R-dihydroxy-vitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MP-lpr/lpr mice. Int. Arch. Allergy Appl. Immunol. 1985, 77:396-404.
223. Lemire J.M. Immunomodulatory role of 1,25-dihydroxyvitamin D3. J. Cell Biochem. 1992, 49:26-31.